<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00790946</url>
  </required_header>
  <id_info>
    <org_study_id>CVM-RCT-2006-06</org_study_id>
    <nct_id>NCT00790946</nct_id>
  </id_info>
  <brief_title>Kagoshima Collaborate Trial in Metabolic Syndrome (KACT Study)</brief_title>
  <acronym>KACT</acronym>
  <official_title>Effects of Valsartan on Metabolic Syndrome in Patients With Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kagoshima University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kagoshima University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to consider the following points in patients with hypertension
      who complicated by metabolic syndrome for Valsartan basis treatment and an existing, standard
      treatment.

        -  Blood pressure control

        -  Changing of adiponectin and plasminogen activator inhibitor-1

        -  Influence metabolizing and cardiac function, etc.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary endpoints are:

        -  blood pressure control

        -  Adiponectin and plasma type1 plasminogen active inhibitor

      The secondary endpoints are

        -  HOMA-IR

        -  HbA1c

        -  TNF-α

        -  IL-6

        -  Plasma B-type natriuretic peptide

        -  LVMI

        -  E/A ratio

        -  Tei-index

        -  Apo-J
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2006</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Pressure, Adiponectin and PAI-1 concentration</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HOMA-IR</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNF-α</measure>
    <time_frame>１ year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BNP</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVMI</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>E/A ratio</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tei-index</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apo-J</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Hypertension</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Valsartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Valsartan 80 to 160mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <description>Valsartan 80 to 160 mg</description>
    <arm_group_label>Valsartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Out patients with hypertension male and female

          -  Systolic blood pressure (SBP)≧140mmHg and/or diastolic blood pressure (DBP)≧90 mmHg

          -  Waist Surrounding diameter male≧85cm female≧90cm

          -  Patient who is treating either high triglyceride,low HDL,or diabetes mellitus

          -  Patient who is untreatment high triglyceride blood syndrome and low HDL blood
             syndrome,diabetes mellitus is triglceride≧150mg/dl and/or HDL cholesterol &lt; 40 mg/dl
             or fasting blood glucose ≧110 mg/dl

          -  Untreated patients with hypertension,or patients is treated with antihypertensive
             agents except for ACE-I and ARB

        Exclusion Criteria:

          -  Patient who is using ACE-I and ARB

          -  Serum creatinine ≧ 3 mg/dl

          -  Liver impairment

          -  History of allergy to valsartan

          -  Pregnant women

          -  Judgment by the physician that participation was unwise on the basis of patient
             characteristics and drug safety
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chuwa Tei, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Cardiovascular,Respiratory &amp; Metabolic Medicine Granduate School of Medicine Kagoshima University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chuwa Tei, MD, PhD</last_name>
    <email>tei@m.kufm.kagoshima-u.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Masaaki Miyata, MD, PhD</last_name>
    <phone>＋81-99-275-5318</phone>
    <email>miyatam@m3.kufm.kagoshima-u.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chuwa Tei,MD,FACC,FAHA</name>
      <address>
        <city>Kagoshima</city>
        <zip>890-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chuwa Tei, MD,FACC,FAHA</last_name>
      <email>tei@m.kufm.kagoshima-u.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Masaaki Miyata, MD,PhD、FACC</last_name>
      <email>miyatam@m3.kufm.kagoshima-u.ac.jp</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2008</study_first_submitted>
  <study_first_submitted_qc>November 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2008</study_first_posted>
  <last_update_submitted>June 2, 2010</last_update_submitted>
  <last_update_submitted_qc>June 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>Chuwa Tei / Professor</name_title>
    <organization>Kagoshima University</organization>
  </responsible_party>
  <keyword>valsartan</keyword>
  <keyword>Metabolic syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

